PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Butterwire is a professional research and portfolio analyst platform designed for high conviction low turnover active equity managers. Butterwire's AI web application was launched in June 2018 and is used by all active equity investors aiming to generate higher returns, with faster stock selection, longer investment horizons, lower portfolio risk, and less trading. The application assists active investors with their top 3 challenges: find opportunities, minimise risk, and keep aware. It is built by and for professionals but is accessible to individual investors, too. The company will utilize 10% of the proceeds to operations, 25% to development, 15% to research, 40% to business development, and 10% to administration.
days to go:
Expired
investment:
Withheld
epaysecure is a secure payment system, which offers comprehensive payment and benefit options, and allows all the services the consumer demands to be offered in one card and e-account. The prepaid business purchasing in European markets is estimated to be $700 million. The company operates in an e-banking and financial services marketing sector that helps clients by identifying new markets and bringing in new ideas to develop them through reloadable products and e-Wallet platform. The funds will be used for staffing, set up costs, other overheads including property marketing and general office costs.
days to go:
Expired
investment:
£168,340
FinOptix is an innovative FinTech company that solves real business problems. FinOptix’s objective is to become a significant player in a rapidly growing FinTech market by developing systems that provide financial clarity to decision-makers. FinOptix has a well-established user base, as well as a sales pipeline that covers multiple geographies and sectors. Their verification and validation procedures applied during the development process and operational trials have led to engagement with commercial partners. With the proceeds, they will design an Evaluator for the future, apply AI techniques to solve complex problems, develop their skill set and framework and hire a team of data scientists based on the assessment.
days to go:
Expired
investment:
£125,000
An IT recruitment and training site launched to meet the demands of enterprises that require highly skilled tech professionals. 365 Talent Portal offers companies to hire IT consultants at a lower price compared to traditional recruitment hubs. The company also allows IT professionals registered on the site to access training and certification programmes that will expand their current skillset and become more marketable to potential employers.
365 Talent Portal is raising funds to produce more prominent marketing campaigns and establish their brand in major markets such as the USA. In addition to this, the company will be using AI more heavily and develop a more automated approach on their platform for their customers.
days to go:
Expired
investment:
£156,000
Doc2UK is a specialist UK medical recruitment and candidate support platform. Based in London, the platform places qualified doctors in the National Health Scheme (NHS) roles around the United Kingdom. The British Medical Association (2018) reported that patient care is at risk due to a critical shortage of doctors across multiple medical disciplines. At present, the UK only has 24 medical schools to fill this gap, whilst India, in comparison, has 468 medical schools, with 68,000 doctors graduating each year. Moreover, uncertainty about the status of EU nationals after Brexit, changes to immigration policies, and the impact of changing language testing requirements for international nurses have made this crisis worse. This situation necessitates recruiting doctors from overseas an important endeavour. This is where Doc2UK aims to become a key player and ensure that lack of medical personnel doesn't disrupt any medical services. The company is seeking an investment of up to £300,000 which will be used to develop the platform with more features, expand the team, marketing and sales.
days to go:
Expired
investment:
Withheld
Intelligent Health aim to get the whole community active by providing games and incentives such as ''beat the street''. By providing schools and communities with friendly competition to walk and cycle more by tapping their cards on ''beat boxes'', and with prizes and league tables on offer, Intelligent health are bringing communities together.
days to go:
Expired
investment:
£700,000
